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In this issue of Cancer Cell, Shaked et al. (2008) provide novel mechanistic evidence that some chemother-
apeutics induce circulating endothelial progenitor (CEP) mobilization with subsequent homing to tumor
vasculature. Addition of an anti-VEGFR2 antibody increased antitumor activity only in combination with
CEP-mobilizing chemotherapeutics. Here we discuss the implications of this work.How does chemotherapy work? Every
practicing oncologist has struggled to
answer this seemingly simple question.
Initially thought to simply inhibit tumor
cell proliferation, additional mechanisms
of action for chemotherapy continue to
emerge. In this issue of Cancer Cell,
Shaked et al. (2008) add vascular disrupt-
ing agents (VDAs) to the list. VDAs are dis-
tinct from antiangiogenic agents, causing
rapid shutdown of the established tumor
vasculature, leading to intratumoral ne-
crosis, and leaving a viable tumor rim. In
earlier work, Shaked et al. (2006) reported
that treatment of tumor-bearing mice with
VDAs leads to acute mobilization of circu-
lating endothelial progenitors (CEPs),
which home to the viable tumor rim. Fur-
thermore, blockage of the VDA-induced
CEP spike by an antiangiogenic drug re-
duces the tumor rim size and blood flow,
thereby enhancing antitumor activity.
Here Shaked et al. demonstrate that
some, but importantly not all, chemother-
apeutics induce acute CEP mobilization
when administered near the maximum
tolerated dose (MTD). As in the investiga-
tors’ previous studies, the mobilized
CEPs subsequently homed to the tumor
vasculature and contributed to tumor
recovery. CEP mobilization was at least
partly mediated by SDF-1a and inhibited
by anti-VEGFR2 antibodies. Notably, the
addition of the anti-VEGFR2 antibody
only augmented the effect of chemother-
apy agents that induced CEP mobiliza-
tion.
So what are CEPs? Confusion and con-
troversy abound. The field has been ham-
pered by differing methodologies and
conflicting nomenclature, a problem com-
pounded by the antigenic promiscuity of
related cell populations including CEPs(called EPCs by some investigators), cir-
culating endothelial cells (CECs), hemato-
poietic progenitor cells (HPCs), heman-
giocytes, Tie2-expressing monocytes
(TEMs), and others. Using in vitro cell cul-
ture and in vivo functional assays, Yoder
et al. (2007) redefined two distinct popula-
tions of bone marrow-derived progenitor
cells. ‘‘Endothelial colony-forming cells’’
(ECFCs, also known as late-outgrowth
EPCs) are the true endothelial progenitor
cells, with high proliferative potential and
vessel-forming activity in vivo. These
rare ECFCs are distinct from the more
common ‘‘colony-forming unit-endothe-
lial cells’’ (CFU-ECs, also known as
early-outgrowth EPCs), which facilitate
angiogenesis but do not form secondary
endothelial cell colonies or perfused ves-
sels in vivo. Alternatively, CEPs can be
defined based on specific cell surface
antigen expression and enumerated by
flow cytometry. Though flow cytometry
ensures enumeration of a homogeneous
population and is more easily applied to
the clinic, the definition of CEPs by this
method is complicated by the absence
of unique CEP markers and the uncer-
tainty of cell lineage and function of the
defined cell populations. For example,
CD34+AC133+VEGFR2+ cells, identified
as CEPs in the majority of studies, do
not form colonies in endothelial clono-
genic assays and are devoid of vessel-
forming activity in vivo but do form colo-
nies using hematopoietic assays and
express the hematopoietic lineage-spe-
cific antigen CD45 (Case et al., 2007).
Though protocols for enumerating distinct
EPC populations by multiparameter flow
cytometry have been proposed, the true
origin and function of these subpopula-
tions have not been assessed by eitherCancer Cell 14,endothelial or hematopoietic clonogenic
assays. Cross-study comparisons and
our understanding of the functional role
of these cell populations will remain lim-
ited until agreement on common nomen-
clature and methodology is reached.
A communal sense of de´ja` vu is
justified here. Previous studies have
suggested that some, though not all, con-
ventional cytotoxics have distinct antian-
giogenic activity (reviewed in Miller et al.,
2001). Most convincingly shown for the
taxanes, cyclophosphamide, and vin-
blastine, antiangiogenic activity requires
lower doses but more consistent admin-
istration—so-called ‘‘metronomic’’ ther-
apy. In contrast to the MTD schedules
used by Shaked et al. (2008), metronomic
therapy decreases CEP mobilization
(Bertolini et al., 2003). Despite the wealth
of compelling laboratory data, direct clin-
ical evidence for either the vascular-
damaging or antiangiogenic activity of
paclitaxel is limited. Consistent with a vas-
cular-damaging effect, CEPs and SDF-1a
levels increased acutely in patients
treated with paclitaxel-based regimens
but did not change in patients treated
with other agents (Shaked et al., 2008).
Consistent with an antiangiogenic effect,
Taghian et al. (2005) reported that pacli-
taxel but not doxorubicin significantly de-
creases tumor interstitial fluid pressure
and increases tumor oxygenation inde-
pendent of tumor size and response. So
which schedule is optimal? Both increas-
ing the frequency of MTD paclitaxel (pre-
sumably increasing the vascular-damag-
ing effect; Citron et al., 2003) and weekly
administration of lower doses (presum-
ably increasing the antiangiogenic effect;
Sparano et al., 2007) are superior to
every-3-weeks administration. DirectSeptember 9, 2008 ª2008 Elsevier Inc. 195
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PreviewsTable 1. Bevacizumab-Based Regimens as Initial Chemotherapy for Metastatic Breast Cancer
E2100 (Miller et al., 2007) AVADO (Miles et al., 2008) XCALIBr (Sledge et al., 2007)
Chemotherapy
paclitaxel 90 mg/m2
d1, 8, 15 q28d docetaxel 100 mg/m2 q21d
capecitabine 1000 mg/m2 bid
d1–14 q21d
Bevacizumab 10 mg/kg q2wks none 15 mg/kg q3wks 7.5 mg/kg q3wks placebo q3wks 15 mg/kg q3wks
Patients enrolled 347 326 247 248 241 106
Prior adjuvant
chemotherapy (%)
56.5 55.5 68 65 65 65
Prior adjuvant
taxane (%)
17.3 14.7 17 15 15 26.2
ER+ (%) 59.9 62.9 76a 78a 78a 54
HER2+ (%) 1.4 0.9 0 0 0 0
ORR (%) 36.9 21.2 63b 55b 44b 38b
PFS (months) 11.8 5.9 8.8 8.7 8.0 5.7
ER+, estrogen receptor-positive; HER2+, human epidermal growth factor receptor 2-positive; ORR, overall response rate; PFS, progression-free
survival.
a Includes patients with ER+ and/or progesterone receptor-positive (PR+) disease.
bORR only reported in patients with measurable disease at study entry.comparisons of these strategies have not
been reported.
This study challenges our assumptions,
and in doing so should both inform future
trial design and enrich our interpretation
of unexpected results. Many have as-
sumed that the addition of an antiangio-
genic to any chemotherapeutic (at any
dose and schedule) would result in a simi-
lar improvement in outcome. Conse-
quently, selection of combinations for
clinical investigation has all too frequently
been guided by regulatory rather than bi-
ologic considerations. Major differences
in progression-free survival (PFS) in three
clinical trials incorporating bevacizumab
into the initial chemotherapy of women
with metastatic breast cancer have been
largely attributed to relatively minor differ-
ences in the patient population and the
duration of chemotherapy (Table 1). The
work of Shaked et al. (2008) offers another
plausible explanation, namely that some
chemotherapy agents offer potential
mechanistic synergy that others lack.
Similarly, correlative efforts in previous tri-
als, largely focusedonchanges in circulat-
ing angiogenic peptides and endothelial
surface antigens after weeks of therapy,
have failed to identify reliable surrogates.196 Cancer Cell 14, September 9, 2008 ª20Here, again, the work of Shaked et al. is
instructive: perhaps our search has been
both in the wrong place and at the wrong
time. While it took decades to redefine
the target of chemotherapy, first as antian-
giogenic and now as VDA, Shaked et al.
force us to redefine the target of antiangio-
genic therapy as well, from simply inhibit-
ingendothelial proliferation toblocking the
host response to vascular damage. We
dare not assume that all antiangiogenic
agents will share this activity. Perhaps
most importantly, Shaked et al. remind
us that the way forward continues to lie
in increased knowledge of fundamental
biology. Francis Bacon’s words still ring
true: ‘‘Nature to be commanded must first
be obeyed.’’
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